Thompson Davis & Co’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Thompson Davis & Co’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$62K	Buy	+68	New	+$44.9K	0.14%	165

Other funds holding HTGM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

PWP

Private Wealth Partners Mill Valley, California $1.3B AUM 26.2% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Thompson Davis & Co's HTGM Position: Q3 2018 in Review

Thompson Davis & Co opened a new position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2018: 68 shares worth $62K. The stake represents 0.14% of the portfolio and ranks #165 among its holdings.

54 funds tracked by Wall St. Rank hold HTGM as of Q3 2018.

Thompson Davis & Co held 68 shares of HTG Molecular Diagnostics, Inc. Common Stock worth $62K as of Q3 2018.
HTG Molecular Diagnostics, Inc. Common Stock was a new Thompson Davis & Co position in Q3 2018.
HTG Molecular Diagnostics, Inc. Common Stock made up 0.14% of Thompson Davis & Co's portfolio in Q3 2018, its #165 holding.
54 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.